Syngene International Ltd

Syngene Intl. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Syngene International Ltd

₹ 699 -0.07%
26 Apr - close price
syngeneintl.com BSE: 539268 NSE : SYNGENE
About

Syngene (established in 1993) as a Biocon subsidiary is India's first Contract Research Organization (CRO) which expanded later to be an integrated service provider offering end-to-end drug discovery, development, and manufacturing services on a single platform (CRAMS). Total research & manufacturing infrastructure for the company is spread across 1.9 million square feet across locations. [1]

Key Points

Business Footprint:[1]
The company caters to diverse end-user industries like Pharmaceuticals, Animal Health, Agrochemicals, Consumer Packaged Goods, Chemicals/Polymers.
It has 400+ active customers with engagements with 13 out of the top 15 global pharma companies. The company holds 400+ patents jointly with clients and has a base of 6000+ scientists.

Website BSE NSE
  • Market Cap ₹ 28,127 Cr.
  • Current Price ₹ 699
  • High / Low ₹ 860 / 652
  • Stock P/E 54.2
  • Book Value ₹ 106
  • Dividend Yield 0.18 %
  • ROCE 14.7 %
  • ROE 13.2 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has reduced debt.
  • Debtor days have improved from 59.3 to 46.2 days.

Cons

  • Stock is trading at 6.60 times its book value
  • Company has a low return on equity of 13.4% over last 3 years.
  • Dividend payout has been low at 10.3% of profits over last 3 years
  • Promoter holding has decreased over last 3 years: -15.8%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
659 594 610 641 758 644 768 786 994 808 910 854 917
443 430 433 438 508 472 552 555 680 596 656 622 600
Operating Profit 215 165 177 203 250 173 216 231 314 212 254 232 317
OPM % 33% 28% 29% 32% 33% 27% 28% 29% 32% 26% 28% 27% 35%
53 12 -18 13 15 16 15 17 23 24 14 26 16
Interest 7 8 1 9 6 9 12 14 10 10 13 11 13
Depreciation 70 75 76 78 80 86 90 95 96 102 105 108 111
Profit before tax 192 95 82 128 179 93 130 140 231 123 151 138 209
Tax % 16% 18% 19% 19% 17% 20% 22% 22% 23% 24% 23% 19% 10%
161 77 67 104 148 74 102 110 179 93 116 112 189
EPS in Rs 4.02 1.93 1.66 2.59 3.69 1.84 2.54 2.73 4.45 2.32 2.90 2.77 4.69
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
1,423 1,826 2,012 2,184 2,604 3,193 3,489
949 1,289 1,394 1,507 1,806 2,251 2,474
Operating Profit 474 537 618 678 798 942 1,014
OPM % 33% 29% 31% 31% 31% 30% 29%
53 75 153 94 20 63 80
Interest 23 32 35 28 24 45 47
Depreciation 131 164 219 274 310 366 426
Profit before tax 372 415 517 469 484 594 621
Tax % 18% 20% 20% 14% 18% 22% 18%
305 332 412 405 396 464 510
EPS in Rs 7.64 8.29 10.30 10.12 9.88 11.57 12.69
Dividend Payout % 7% 3% 0% 0% 10% 11% 10%
Compounded Sales Growth
10 Years: %
5 Years: 14%
3 Years: 17%
TTM: 9%
Compounded Profit Growth
10 Years: %
5 Years: 10%
3 Years: 11%
TTM: 12%
Stock Price CAGR
10 Years: %
5 Years: 18%
3 Years: 5%
1 Year: 8%
Return on Equity
10 Years: %
5 Years: 14%
3 Years: 13%
Last Year: 13%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity Capital 200 200 400 400 401 401 402
Reserves 1,520 1,768 1,776 2,421 2,897 3,217 3,856
787 813 773 893 1,022 815 555
681 922 1,214 1,169 1,245 1,398 1,339
Total Liabilities 3,189 3,704 4,163 4,883 5,564 5,831 6,152
1,030 1,377 2,020 2,201 2,393 2,667 2,851
CWIP 155 274 234 237 346 177 837
Investments 158 716 776 702 1,034 918 548
1,846 1,337 1,133 1,743 1,790 2,069 1,916
Total Assets 3,189 3,704 4,163 4,883 5,564 5,831 6,152

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
446 630 677 701 581 824 1,042
-349 -646 -424 -629 -611 -653 -496
-79 -72 -226 58 -31 -342 -552
Net Cash Flow 18 -88 28 130 -62 -172 -5

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 68 68 72 79 71 61 46
Inventory Days 82 30 18 41 87 141 94
Days Payable 195 154 156 167 113 109 100
Cash Conversion Cycle -44 -56 -66 -47 45 92 40
Working Capital Days -28 -65 -115 -20 -3 -1 36
ROCE % 17% 17% 14% 13% 15%

Shareholding Pattern

Numbers in percentages

8 Recently
Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
70.43% 70.42% 70.41% 70.41% 70.29% 64.86% 64.86% 54.88% 54.80% 54.79% 54.79% 54.79%
14.42% 14.09% 13.84% 13.69% 14.15% 16.79% 16.87% 23.31% 23.19% 23.55% 21.20% 20.92%
4.75% 4.80% 4.41% 4.41% 4.18% 6.75% 7.03% 10.71% 11.20% 11.70% 14.63% 15.80%
9.49% 9.82% 10.61% 10.81% 10.56% 11.11% 10.77% 10.65% 10.23% 9.47% 9.07% 8.17%
0.90% 0.86% 0.72% 0.68% 0.83% 0.49% 0.47% 0.46% 0.60% 0.48% 0.32% 0.00%
No. of Shareholders 1,26,3951,36,7491,37,8921,33,6101,28,2781,34,3341,27,9641,24,0141,25,4551,25,9921,21,8801,15,850

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls